| Date | Time | Source | Headline | Symbol | Company |
| 09/26/2024 | 1:00AM | UK Regulatory | Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis | LSE:0QQ6 | Roche Holding Ag |
| 09/24/2024 | 1:00AM | UK Regulatory | Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses | LSE:0QQ6 | Roche Holding Ag |
| 09/23/2024 | 1:00AM | UK Regulatory | WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions | LSE:0QQ6 | Roche Holding Ag |
| 09/19/2024 | 1:00AM | UK Regulatory | Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses | LSE:0QQ6 | Roche Holding Ag |
| 09/16/2024 | 1:00AM | UK Regulatory | FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis | LSE:0QQ6 | Roche Holding Ag |
| 09/13/2024 | 1:00AM | UK Regulatory | FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy | LSE:0QQ6 | Roche Holding Ag |
| 09/10/2024 | 10:00AM | UK Regulatory | Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen | LSE:0QQ6 | Roche Holding Ag |
| 09/10/2024 | 10:00AM | UK Regulatory | Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation | LSE:0QQ6 | Roche Holding Ag |
| 09/04/2024 | 2:00AM | UK Regulatory | Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis | LSE:0QQ6 | Roche Holding Ag |
| 08/27/2024 | 1:00AM | UK Regulatory | Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH | LSE:0QQ6 | Roche Holding Ag |
| 08/20/2024 | 8:30AM | UK Regulatory | Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak | LSE:0QQ6 | Roche Holding Ag |
| 07/30/2024 | 1:00AM | UK Regulatory | European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) | LSE:0QQ6 | Roche Holding Ag |
| 07/29/2024 | 1:00AM | UK Regulatory | Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care | LSE:0QQ6 | Roche Holding Ag |
| 07/25/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised | LSE:0QQ6 | Roche Holding Ag |
| 07/18/2024 | 7:20AM | UK Regulatory | New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions | LSE:0QQ6 | Roche Holding Ag |
| 07/17/2024 | 11:45AM | UK Regulatory | Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study | LSE:0QQ6 | Roche Holding Ag |
| 07/17/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity | LSE:0QQ6 | Roche Holding Ag |
| 07/09/2024 | 1:00AM | UK Regulatory | Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes | LSE:0QQ6 | Roche Holding Ag |
| 07/08/2024 | 11:45AM | UK Regulatory | Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) | LSE:0QQ6 | Roche Holding Ag |
| 07/05/2024 | 1:00AM | UK Regulatory | FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss | LSE:0QQ6 | Roche Holding Ag |
| 07/04/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer | LSE:0QQ6 | Roche Holding Ag |
| 06/28/2024 | 7:15AM | UK Regulatory | Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) | LSE:0QQ6 | Roche Holding Ag |
| 06/28/2024 | 7:00AM | UK Regulatory | CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition | LSE:0QQ6 | Roche Holding Ag |
| 06/27/2024 | 1:00AM | UK Regulatory | Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection | LSE:0QQ6 | Roche Holding Ag |
| 06/25/2024 | 1:00AM | UK Regulatory | Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis | LSE:0QQ6 | Roche Holding Ag |
| 06/24/2024 | 1:00AM | UK Regulatory | Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories | LSE:0QQ6 | Roche Holding Ag |
| 06/20/2024 | 1:00AM | UK Regulatory | Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma | LSE:0QQ6 | Roche Holding Ag |
| 06/15/2024 | 10:00AM | UK Regulatory | Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma | LSE:0QQ6 | Roche Holding Ag |
| 06/10/2024 | 1:05AM | UK Regulatory | Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization | LSE:0QQ6 | Roche Holding Ag |
| 06/10/2024 | 1:00AM | UK Regulatory | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer | LSE:0QQ6 | Roche Holding Ag |